WUSTL Expands Patient Pool for WGS Cancer Test After CMS Coverage Milestone

A whole-genome sequencing test developed by researchers at Washington University School of Medicine in Saint Louis (WUSTL) has received coverage from the US Centers for Medicare and Medicaid Services, allowing the assay to be employed across a wider group of patients.

The ChromoSeq test is a high-coverage whole-genome assay for patients with myeloid neoplasms that runs on Illumina sequencers, said Eric Duncavage, a professor of pathology and immunology at the university and one of the developers of the test. The team has been using the assay to test patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in its hospitals since 2021, but its CMS coverage will allow the university to widen its pool of potential patients.

Source: https://www.genomeweb.com/cancer/wustl-expands-patient-pool-wgs-cancer-test-after-cms-coverage-milestone